Free Shipping on Orders Over $100
News2018-03-22T04:59:36+00:00

News

2507, 2019

Helping Biotech Startups Grow

By |July 25th, 2019|Categories: Latest Publications|Tags: , , , |Comments Off on Helping Biotech Startups Grow

For more than 30 years, University of Wisconsin-Madison affiliate University Research Park has been a hotspot for innovation in engineering, computational and life sciences. As your community energy company, MGE and its philanthropic arm, the MGE Foundation, are helping to advance the next generation of innovation by supporting Forward BIOLABS. With the goal of helping life science startup companies succeed, the incubator on Madison's west side provides fully equipped and supported lab space that helps companies focus on their work. The model eliminates the need for these companies to lease, equip and operate their own labs. "Startups can move so much more quickly with Forward BIOLABS' laboratories and supportive environment. These powerful tools enable early stage companies to operate efficiently while they advance cutting-edge technologies in areas like oncology, regenerative medicine and agriculture," Forward BIOLABS Co-founder Jessica Martin Eckerly stated. In addition to the benefits of a turnkey, state-of-the-art lab space, Forward BIOLABS facilitates interactions between members, lab service providers, investors, industry and academia. Advancing innovation, entrepreneurship for decades A longtime partner in advancing innovation and entrepreneurship throughout the Madison area, MGE in 1989 partnered with University Research Park to establish the MGE Innovation Center to help early stage companies cultivate their technologies for real-world applications. The center is a hub for Wisconsin’s thriving biohealth industry, which is responsible for an estimated $48 billion in economic output and more than 100,000 jobs created in the state. Beyond the numbers, supporting biotech and Forward BIOLABS means changing lives outside of the labs. From developing groundbreaking cell therapies to treat children with serious illnesses to manufacturing tissues for treating brain tumors and building better medical devices, the industry is poised to produce a wide array of next-generation healthcare solutions.   Source: https://www.mgeenergy.com/news/20190614-helping-biotech-startups-grow.htm

603, 2018

Synthetic Genomics Launches Vmax™ Express, a Next-Generation Protein Expression Platform for the Biotech Industry Vmax™ Express is designed to replace E. coli-based platforms for manufacturing recombinant proteins and biologic drugs

By |March 6th, 2018|Categories: Latest Publications|Comments Off on Synthetic Genomics Launches Vmax™ Express, a Next-Generation Protein Expression Platform for the Biotech Industry Vmax™ Express is designed to replace E. coli-based platforms for manufacturing recombinant proteins and biologic drugs

LA JOLLA, CA — January 9, 2017 — Synthetic Genomics Inc. announced today that its subsidiary, SGI-DNA, has launched Vmax™ Express, a highly advanced bacterial host organism designed for significant improvement in recombinant protein expression. Compatible with standard plasmids, antibiotics and growth media used in other bacterial protein expression systems, Vmax™ Express generates larger amounts of soluble recombinant proteins faster and more efficiently than E. coli-based systems. “E. coli host organisms have been tweaked for incremental refinement for decades, but the development and commercialization of Vmax™ Express marks a dramatic step forward,” said Daniel Gibson, Ph.D., vice president of DNA technologies at Synthetic Genomics. “Our team of scientists began with a clean slate — unconstrained by the inherent limitations of E. coli — and designed a novel, advanced, fast-growing host organism that will translate into next-generation protein production in the research as well as biopharma and industrial biotechnology production settings.” E. coli is the most widely-used organism in molecular genetic research and accounts for the production of 30 percent of FDA-approved biologic drugs. Vmax™ Express can replace slow-growing E. coli systems, which are prone to low yields and the expression of insoluble protein. Vmax™ Express offers several advantages over E. coli including: higher levels of protein expression (Vmax™ Express delivers at least double the amount of protein per milliliter); increased speed (approximate two-fold improvement in replication time); increased compatibility with a range of proteins that may be difficult to express in E. coli; and rapid results: protein purification in three days (one full day faster than E. coli, from cells to large-scale culture). Vmax™ Express is derived from the marine microorganism Vibrio natriegens, a gram-negative, non-pathogenic bacterium that exhibits the fastest growth rate of any known organism. Vmax™ [...]

2302, 2018

Mylan Receives Tentative Approval for Combination HIV Treatment Under FDA’s PEPFAR Program

By |February 23rd, 2018|Categories: Latest Publications|Comments Off on Mylan Receives Tentative Approval for Combination HIV Treatment Under FDA’s PEPFAR Program

HERTFORDSHIRE, England and PITTSBURGH, Feb. 20, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced receipt of tentative approval from the U.S. Food and Drug Administration (FDA) under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, 50 mg/200 mg/25 mg. The antiretroviral (ARV) will be immediately available in developing countries as a first-line regimen for people being treated for HIV/AIDS. Mylan is the world's largest producer of HIV/AIDS drugs, and more than 40% of people being treated worldwide for HIV/AIDS depend on a Mylan antiretroviral product. "The FDA's tentative approval of Mylan's Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Tablets sets a new standard for affordable access for patients in countries hardest hit by HIV, as it's the first time a product combines dolutegravir and tenofovir alafenamide," said Mylan CEO Heather Bresch. "With limited funding, the world needs cost competitive and clinically effective products like this one, and Mylan is proud to work with partners to make it available and help reach the more than 15 million people living with HIV worldwide who still need access to treatment." Mylan's ARV is a once-daily, fixed-dose combination of Dolutegravir, Emtricitabine and Tenofovir Alafenamide, the individual components that make up ViiV Healthcare's Tivicay® and Gilead's Descovy®. Mylan manufactures these products under licenses from the Medicines Patent Pool and Gilead Sciences, respectively. This is the first tentative approval of Tenofovir Alafenamide and comes just two years after the FDA approval of Descovy®. The combination of these agents is currently included as a "Recommended Initial Regimen for Most People with HIV" in the HIV guidelines of the U.S. Department of Health and Human Services. "In the past decade, Mylan has committed itself again and again to bringing new [...]

1112, 2017

Midwest Biotech Supply Launches Offerings to Support Biotech Companies Focused on Improving the Human Condition

By |December 11th, 2017|Categories: In the press, Latest Publications|Comments Off on Midwest Biotech Supply Launches Offerings to Support Biotech Companies Focused on Improving the Human Condition

Madison, WI (December 11th, 2017) – Midwest Biotech Supply (MBS), a division of Wallo Brands, today announced its launch and offerings of research services and products such as custom protein expression and purification and production of essential biotechnology reagents. MBS is launching with the commitment to improve the world through biotechnology.“Biotechnology is at the forefront of providing answers to the most perilous illnesses that we face,” stated Victor Agapov, Principal of Midwest Biotech Supply. “By offering other biotech companies an opportunity to outsource the production of custom reagents, such as recombinant proteins and their derivatives, we enable these companies to focus on world-changing research.”MBS will launch their initial products on December 11th, including:Protein A agarose (recombinant, E. coli)Protein G agarose (recombinant, E. coli)Streptavidin agarose and tagged purified Streptavidin (recombinant, E. coli). These products will be available in a variety of sizes, with volumes ranging from 25 ml to 5 L. Custom size lots will also be available.MBS is certified by the USBLN with a DOBE certification. Based in Madison, WI, the company partners with local communities and businesses and has access to the resources of the University of Wisconsin, which facilitates MBS’s advances in developing new products. Other business-to-business services will soon include:Production of recombinant proteins in Pichia Pastoris yeast.Production of recombinant proteins in mammalian cells.“Our goal is to foster a collaborative environment for further discovery and innovation,” continued Agapov. “As a newly-launched company, MBS is actively seeking partners who share our vision and can benefit from our products and expertise as well as collaborative efforts in further product development.”About Midwest Biotech SupplyMidwest Biotech Supply is a registered dba of Wallo Brands LLC, a Madison, WI based B2B Biotechnology Company which specializes in providing products and services to other [...]